Equities

Jinyu Bio-Technology Co Ltd

600201:SHH

Jinyu Bio-Technology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)5.80
  • Today's Change-0.06 / -1.02%
  • Shares traded9.58m
  • 1 Year change-38.23%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,7201,4421,517
Total Receivables, Net914874905
Total Inventory322333318
Prepaid expenses282120
Other current assets, total32101.08
Total current assets3,0162,6812,761
Property, plant & equipment, net1,8931,8001,822
Goodwill, net112995
Intangibles, net729669649
Long term investments1,1251,1231,166
Note receivable - long term------
Other long term assets----26
Total assets6,8736,3896,604
LIABILITIES
Accounts payable306341342
Accrued expenses797983
Notes payable/short-term debt413316
Current portion long-term debt/capital leases1.530.530.62
Other current liabilities, total412205248
Total current liabilities840659689
Total long term debt2.730.310.16
Total debt463417
Deferred income tax9.631010
Minority interest288277288
Other liabilities, total365370344
Total liabilities1,5061,3171,332
SHAREHOLDERS EQUITY
Common stock1,1201,1201,126
Additional paid-in capital892834893
Retained earnings (accumulated deficit)3,6733,4563,366
Treasury stock - common(338)(338)(113)
Unrealized gain (loss)20(0.49)(0.3)
Other equity, total0.060.080.07
Total equity5,3675,0725,272
Total liabilities & shareholders' equity6,8736,3896,604
Total common shares outstanding1,0871,0871,120
Treasury shares - common primary issue33335.83
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.